INTERIM report LIDDS AB (publ) 556580-2856
THE FIRST QUARTER (JANUARY – MARCH 2017)
-
Net sales amounted to SEK 0 (0)
-
The costs amounted to sek 1.8 million (1.5) M
-
The profit before and after tax was msek -1,8 (-1,5) M
-
Earnings per share amounted to sek 0.10 (-0,11) $
SIGNIFICANT EVENTS DURING THE FIRST QUARTER OF
-
The placebo-controlled preclinical study with NanoZolid® and docetaxel has been accepted for publication in European Journal of Pharmaceutics and Biopharmaceutics. NanoZolid with docetaxel injection directly into the tumor gave equally good results on the lung cancer cells as in the systemic treatment but without giving the typical side effects seen with systemic treatment. The results attracted great interest at the European lungcancerkongressen in Geneva on 7 may.
-
LIDDS has, in collaboration with the IGP, Uppsala University demonstrated that antibodies able to is incorporated in the NanoZolid® and released in biological environment while retaining biological function. NanoZolid® would thus be combined with the antibodies in the tumors by local activation of the body’s immune system giving LIDDS access to a highly interesting and growing market.
-
LIDDS has to protect future drug candidates applied for a patent for NanoZolid® in combination with the so far known biomolecules for immunotherapy.
-
An “Investigator meeting” for the LPC 004 has been implemented in Canada, where treatment with Liproca Depot was demonstrated to the study, urologists, coordinators, and nurses. Urologerna expressed a great interest for this new type of treatment of prostate cancer. A world-leading urologist in the field of research on patients who are under “active monitoring”, Professor Laurence Klotz of the university Hospital in Toronto, participating in the study. Prescreening of patients for the LPC-004 has been completed. The study will evaluate the optimal dose of NanoZolid® with 2-hydroxyflutamide, Liproca® Depot, and the product’s impact on the cancermarkörer in the prostate.
SIGNIFICANT EVENTS AFTER THE END OF THE
-
An exclusive product – development and option agreement has been concluded with Belina AB LIDDS shall NanoZolid® formulate a new innovative medicine for Belina. The product shall provide a controlled release of the drug (which is not cytostatic) over a long period of time and used in the treatment of breast cancer.
-
LIDDS was invited to present NanoZolid®technology on the GRIBOI, an international conference on injectable biomaterials.
-
The agency in Canada has approved the clinical study, the LPC-004. Läkemedelsbatchen of Liproca® Depot is approved and urologklinikerna to participate in the study, ready to include patients.
-
A directed new share issue of 4.2 MILLION were made to the Immobilien Österreich AB in april 2017. The owner of this company, Daniel Lifveredson, is proposed as member of the board at the annual general meeting.
The information in this interim report is such that LIDDS is obliged to publish under the EU marknadsmissbruksförordning and the law on the securities market. The information was submitted, by
Monica Wallters in the government, for publication on 11 may 2017 there 08:45 CET.
The news in PDF